Rare Diseases Today—April 30, 2026

This week’s Rare Diseases update highlights regulatory actions, clinical progress, deal activity, platform expansion, financing moves, and safety scrutiny.

In Today’s Newsletter

Dive deeper

🧬 Lilly to acquire Ajax Therapeutics for AJ1-11095 [1] [US • 27 Apr 2026]

https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-ajax-therapeutics-advance-outcomes-patients
Context: AJ1-11095 is an investigational once-daily oral Type II JAK2 inhibitor in Phase 1 AJX-101 for myelofibrosis after Type I JAK2 inhibitor treatment.
Key point: Eli Lilly agreed to acquire Ajax Therapeutics for up to $2.3bn in cash, including upfront and milestone payments.
Implication: Signals pipeline investment and modality expansion.

🧒 Solid wins EU orphan status for SGT-003 in Duchenne [2] [EU • 28 Apr 2026]

https://www.globenewswire.com/news-release/2026/04/28/3282582/0/en/solid-biosciences-announces-receipt-of-european-commission-orphan-drug-designation-for-sgt-003-for-the-treatment-of-duchenne-muscular-dystrophy.html
Context: SGT-003 is being studied in INSPIRE DUCHENNE, a Phase 1/2 trial, and IMPACT DUCHENNE, a Phase 3 randomized, double-blind, placebo-controlled trial.
Key point: Solid Biosciences said the European Commission granted orphan drug designation to SGT-003 for Duchenne muscular dystrophy.
Implication: May influence prescriber choice and payer reviews pending full data.

🫀 FDA grants orphan status to pegrizeprument in heart transplant [3] [US • 27 Apr 2026]

https://www.globenewswire.com/news-release/2026/04/27/3281280/0/en/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101-for-prevention-of-organ-rejection-in-heart-transplant-patients.html
Context: Pegrizeprument (VEL-101) is an investigational immunomodulatory monoclonal monovalent antibody fragment licensed by OSE Immunotherapeutics to Veloxis in 2021.
Key point: FDA granted orphan drug designation to pegrizeprument for prophylaxis of heart allograft rejection in heart transplant patients.
Implication: May influence prescriber choice and payer reviews pending full data.

🧴 Quoin advances QRX009 topical rapamycin studies [4] [US • 28 Apr 2026]

https://www.globenewswire.com/news-release/2026/04/28/3282671/0/en/quoin-pharmaceuticals-provides-clinical-and-regulatory-update-for-qrx009-topical-rapamycin-development-programs.html
Context: QRX009 is Quoin Pharmaceuticals’ topical rapamycin lotion program for rare skin diseases, with investigator-led studies planned.
Key point: Quoin plans studies in pachyonychia congenita, Gorlin syndrome, and tuberous sclerosis complex, plus an FDA IND for another indication in Q3 2026.
Implication: May expand screening, initiation, and follow-up at scale.

🧪 BioMarin completes Amicus acquisition [5] [US • 27 Apr 2026]

https://www.biomarin.com/news/press-releases/biomarin-completes-acquisition-of-amicus-therapeutics/
Context: The acquisition adds Galafold (migalastat) for Fabry disease and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) for Pompe disease.
Key point: BioMarin completed its all-cash acquisition of Amicus Therapeutics for $14.50 per share, about $4.8bn in equity value.
Implication: Signals pipeline investment and modality expansion.

✂️ Intellia starts rolling BLA for lonvo-z in HAE [6] [US • 27 Apr 2026]

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-initiates-rolling-submission-biologics
Context: Lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) is an in vivo CRISPR candidate intended to inactivate KLKB1 in hereditary angioedema.
Key point: Intellia initiated a rolling BLA submission after Phase 3 HAELO met its primary and key secondary endpoints.
Implication: May influence prescriber choice and payer reviews pending full data.

💵 Rocket sells rare pediatric disease PRV for $180m [7] [US • 28 Apr 2026]

https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-announces-180-million-sale-priority
Context: Rocket Pharmaceuticals received the PRV after FDA accelerated approval of KRESLADI (marnetegragene autotemcel).
Key point: Rocket agreed to sell its rare pediatric disease priority review voucher for $180m, extending projected cash runway into Q2 2028.
Implication: Signals pipeline investment and modality expansion.

🇰🇷 Samsung Medical Center builds G-CROWN gene therapy platform [8] [South Korea • 29 Apr 2026]

https://www.news1.kr/amp/bio/general/6152174
Context: G-CROWN is a hospital-led gene therapy development platform for rare and intractable diseases, backed by South Korea’s Ministry of Health and Welfare R&D initiative.
Key point: Samsung Medical Center aims to integrate patient data, disease models, preclinical work, clinical design, and commercialization.
Implication: May expand screening, initiation, and follow-up at scale.

⚠️ FDA proposes Tavneos withdrawal [9] [US • 28 Apr 2026]

https://www.fiercepharma.com/pharma/fda-puts-more-heat-amgen-proposing-rescind-approval-tavneos
Context: Tavneos (avacopan, Amgen) is approved with glucocorticoids and standard-of-care therapy for ANCA-associated vasculitis.
Key point: FDA CDER proposed withdrawing approval, citing concerns over effectiveness, safety, and alleged data manipulation in the pivotal trial.
Implication: Introduces uncertainty that may affect formulary access and treatment planning.

Why it matters

Rare disease deal activity remained active, with Lilly–Ajax and BioMarin–Amicus expanding hematology and lysosomal storage disease portfolios.
Regulatory designations continued to shape development strategy for Solid Biosciences, OSE Immunotherapeutics, and Veloxis.
Intellia’s lonvo-z filing keeps in vivo CRISPR moving toward a potential US approval decision pathway.
Rocket’s PRV sale highlights non-dilutive financing as gene therapy companies manage capital needs.
FDA’s Tavneos action shows rising scrutiny of post-approval data integrity and safety signals.

📚 View the full Rare Disease archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

FAQ

What did Eli Lilly gain from the Ajax Therapeutics deal?

illy would add AJ1-11095, an investigational once-daily oral Type II JAK2 inhibitor in Phase 1 for myelofibrosis after prior Type I JAK2 inhibitor treatment. The deal value is up to $2.3bn in cash. [1]

What is the regulatory significance of SGT-003’s EU orphan drug designation?

Solid Biosciences said the European Commission granted orphan drug designation for SGT-003 in Duchenne muscular dystrophy. The company also cited US and UK designations as part of a global development strategy. [2]

Who controls pegrizeprument (VEL-101) development?

OSE Immunotherapeutics discovered and developed pegrizeprument and licensed it to Veloxis in 2021 for transplant-related indications. Veloxis is responsible for global development, manufacturing, and future commercialization. [3]

What assets did BioMarin add through Amicus?

BioMarin added Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease. It also gained US rights to DMX-200, a Phase 3 investigational small molecule for FSGS. [5]

What is lonvo-z and what did Intellia file?

Lonvo-z is an in vivo CRISPR candidate for hereditary angioedema intended to inactivate KLKB1. Intellia initiated a rolling BLA submission to FDA and expects to complete it in H2 2026. [6]

What is FDA proposing for Tavneos?

FDA CDER proposed withdrawing Tavneos approval, citing concerns about effectiveness, safety, and alleged data manipulation. Amgen said it remains confident in the drug and is evaluating next steps. [9]

Entities / Keywords

Eli Lilly and Company, Lilly, LLY
Ajax Therapeutics, Ajax
AJ1-11095, Type II JAK2 inhibitor, AJX-101
Myelofibrosis, polycythemia vera, myeloproliferative neoplasms, MPNs
Solid Biosciences, SLDB
SGT-003, Duchenne muscular dystrophy, Duchenne, DMD
INSPIRE DUCHENNE, IMPACT DUCHENNE
OSE Immunotherapeutics, Veloxis Pharmaceuticals
Pegrizeprument, VEL-101, heart allograft rejection, heart transplant
Quoin Pharmaceuticals, QNRX
QRX009, topical rapamycin, pachyonychia congenita, Gorlin syndrome, tuberous sclerosis complex
BioMarin Pharmaceutical, BMRN
Amicus Therapeutics, Galafold, migalastat, Pombiliti, cipaglucosidase alfa-atga, Opfolda, miglustat
Fabry disease, Pompe disease, DMX-200, focal segmental glomerulosclerosis, FSGS
Intellia Therapeutics, NTLA
Lonvoguran ziclumeran, lonvo-z, NTLA-2002, hereditary angioedema, HAE, KLKB1, HAELO
Rocket Pharmaceuticals, RCKT
KRESLADI, marnetegragene autotemcel, rare pediatric disease priority review voucher, PRV
Samsung Medical Center, G-CROWN, gene therapy, rare and intractable diseases
Amgen, ChemoCentryx, Tavneos, avacopan, ANCA-associated vasculitis, CDER, FDA
Orphan drug designation, BLA, IND, RMAT, priority review voucher